Antigenics: Getting down to (patient) specifics

Antigenics: Getting down to (patient) specifics

A challenge to developing cancer therapies is that any given cancer in any particular patient is genetically distinct. While a competent immune response may succeed in the elimination of precancerous lesions in some patients, in others a developing cancer may evade the immune system completely.

Building on the activation of the body's immunological response to manage or prevent metastasis, Antigenics has developed a technology that uses a transporter molecule known as heat shock protein (HSP)

Read the full 802 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE